InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,716.80
(
0.19%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.23
(
0.02%
)
Bitcoin
62,330.87
(
-0.91%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 311

Tuesday, 08/21/2018 1:52:24 PM

Tuesday, August 21, 2018 1:52:24 PM

Post# of 438
CERC recently shifted model to include marketed pediatric healthcare treatments and supplements

11/17 Acquired Zylera Pharma. Shkreli touted their new business model as reminiscent of his own acquisition strategies.

It's lead clinical asset is the Ph2 CERC-301, an adjunctive treatment for Major Depressive Disorder.

Balance sheet is heavily laden with intangibles and they only have a cash runway thru 2018.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up